mcd003

Marinos C. Dalakas, MD, FAAN

Contact Dr. Dalakas

909 Walnut Street
3rd Floor
Philadelphia, PA 19107

(215) 955-7952
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition
  2. Immunotherapy in myasthenia gravis in the era of biologics
  3. Quantitative clinical and autoimmune assessments in stiff person syndrome: Evidence for a progressive disorder
  4. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
  5. Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
  6. Myositis: Are autoantibodies pathogenic in necrotizing myopathy?
  7. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
  8. Advances in the diagnosis, immunopathogenesis and therapies of igm-anti-mag antibody-mediated neuropathies
  9. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy
  10. Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy
  11. Gene therapy for Duchenne muscular dystrophy: Balancing good science, marginal efficacy, high emotions and excessive cost
  12. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome
  13. Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors
  14. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome
  15. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
  16. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis
  17. Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations
  18. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business
  19. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  20. Close to the node but far enough